Medial temporal lobectomy is effective in improving seizure outcomes among patients with drug-resistant temporal lobe epilepsy.

Epilepsy in babies should not be underestimated. If seizures occur frequently and continuously, it can affect the growth and ...

for drug-resistant mesial temporal lobe epilepsy (MTLE), which is among the most common types of epilepsy. In an ongoing multicenter, open-label Phase 1/2 trial in adults with drug-resistant MTLE ...

Vaclav Kremen, Ph.D., Mayo Clinic researcher and co-lead author of the study The researchers monitored five patients with temporal lobe epilepsy throughout their DBS treatment. The system allowed ...

The asset, dubbed NRTX-1001, is currently being tested in an open-label phase 1/2 trial among patients with drug-resistant mesial temporal lobe epilepsy ... in which adults with drug-resistant ...

At final follow-up, 15 respondents (75%) reached Engel class I (no seizures) and 5 respondents (25%) reached Engel class II (rare, nondisabling seizures). HealthDay News — Medial temporal ...

Neurona Therapeutics has gained $102m to support the advancement of its investigational cell therapy, NRTX-1001, into Phase III testing for drug-resistant mesial temporal lobe epilepsy (MTLE).

The majority of the patients who committed suicide reported good seizure control prior to their ... contributed to suicidality. Frontal and temporal lobe networks and changes in serotonergic ...

In this study, we aimed to construct ferroptosis-related gene signatures in temporal lobe epilepsy with hippocampal sclerosis (TLE-HS) and explore their diagnostic role in TLE-HS. Methods: The ...

Background A prior study showed that people with temporal lobe epilepsy (TLE) with an active lifestyle present a better quality of life (QoL), but the influence of aerobic physical exercise (APE) in ...